Pharmaceutical Applications of CRISPR Technology

Dr. Olivia J Wilson [1*], Liam A Clarke [2], Dr. Mia R Bennett [3]
[1] PhD, Australian Institute for Pharmaceutical Nanotechnology, University of Sydney, Australia
[2] PhD, Centre for Precision Oncology Drug Delivery, University of Melbourne, Australia
[3] PhD, Institute for Lipid Nanocarrier Systems, Monash University, Australia

* Corresponding Author: **Dr. Olivia J Wilson**

Article Info

ISSN (online): 3107-393X
Volume: 02
Issue: 02
March-April 2025
Received: 25-02-2025
Accepted: 29-03-2025
Published: 23-04-2025
Page No: 22-27

Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and its associated Cas proteins represent a transformative genome-editing platform derived from prokaryotic adaptive immune systems. This technology enables precise, programmable modifications to virtually any genomic locus, making it a powerful tool across biomedical research and pharmaceutical sciences. This review examines the current and emerging pharmaceutical applications of CRISPR technology, with particular emphasis on gene therapy for monogenic disorders, cancer immunotherapy, infectious disease treatment, drug discovery, and precision medicine strategies. Key applications discussed include CRISPR-mediated correction of pathogenic mutations in hemoglobinopathies, development of CAR-T cell therapies, high-throughput functional genomic screening for drug target identification, and generation of relevant disease models. CRISPR systems offer unparalleled advantages including versatility, scalability, low cost, and ease of design compared to earlier genome-editing tools such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). However, significant challenges remain, including off-target editing, efficient *in vivo* delivery, immunogenicity, and complex regulatory landscapes. Ethical concerns surrounding germline editing further complicate clinical translation. Despite these hurdles, early clinical trials have yielded promising results, particularly for sickle cell disease and beta-thalassemia. The continued development of base editing, prime editing, and CRISPR-based diagnostics expands the therapeutic repertoire. Overall, CRISPR technology holds substantial promise for revolutionizing pharmaceutical drug development and personalized medicine in the coming decade.

Keywords: CRISPR-Cas9, gene therapy, precision medicine, drug discovery, genome editing, therapeutic applications

1. Introduction

The advent of CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins) technology has fundamentally reshaped the landscape of molecular biology and pharmaceutical sciences. Originally identified as a bacterial adaptive immune mechanism, CRISPR-Cas systems have been rapidly engineered into versatile genome-editing platforms capable of introducing targeted double-strand breaks (DSBs), modulating gene expression, and delivering epigenetic modifications with exceptional specificity [1, 2].

In pharmaceutical research, the significance of CRISPR lies in its ability to interrogate gene function at scale, validate therapeutic targets, model human diseases, and directly correct pathogenic mutations. The platform's simplicity—requiring only a single guide RNA (sgRNA) and a Cas nuclease—democratized gene editing and accelerated both preclinical and clinical research timelines [3, 4]. Prior genome-editing tools such as ZFNs and TALENs, while effective, were limited by complex protein engineering requirements, higher costs, and lower throughput [5].

The scope of CRISPR applications in pharmaceutical sciences now extends from gene therapy for inherited diseases to immuno-

oncology, antiviral strategies, and the development of next-generation biologics. Landmark approvals such as Casgevy (exagamglogene autotemcel) for sickle cell disease and beta-thalassemia in 2023 underscore the translational maturity of this technology [6]. This review aims to comprehensively examine the pharmaceutical applications of CRISPR, highlighting current therapeutic strategies, drug discovery utilities, challenges, and future directions.

2. CRISPR Technology in Pharmaceutical Research

2.1. CRISPR-Cas Systems and Gene Editing Principles

The CRISPR-Cas9 system from Streptococcus pyogenes remains the most widely used variant in pharmaceutical applications. It operates through a ribonucleoprotein complex in which the Cas9 endonuclease is guided to a complementary genomic locus by a sgRNA. Recognition requires a protospacer-adjacent motif (PAM) sequence (5'-NGG-3' for SpCas9) immediately downstream of the target [7]. Upon binding, Cas9 generates a blunt-ended DSB that is repaired via error-prone non-homologous end joining (NHEJ) or high-fidelity homology-directed repair (HDR), enabling gene disruption or precise correction, respectively [8].

Beyond Cas9, additional effectors such as Cas12a (Cpf1), Cas13, and CasX have expanded the CRISPR toolkit (Table 1). Cas12a generates staggered cuts and recognizes T-rich PAMs, offering advantages in certain genomic contexts [9]. Cas13, which targets RNA rather than DNA, is particularly relevant for transient gene knockdown and antiviral approaches [10]. SaCas9 (from Staphylococcus aureus) and other compact orthologs facilitate delivery via adeno-associated virus (AAV) vectors due to their smaller size [11].

Table 1: Major CRISPR Systems and Their Characteristics

System	Nuclease	PAM	Cut Type	Target	Key Application
CRISPR-Cas9 (SpCas9)	Cas9	5'-NGG-3'	Blunt DSB	dsDNA	Gene KO, HDR correction
CRISPR-Cas12a (Cpf1)	Cas12a	5'-TTTN-3'	Staggered DSB	dsDNA	Gene editing, diagnostics
CRISPR-Cas13	Cas13	None	ssRNA cleavage	ssRNA	Antiviral, knockdown
SaCas9	SaCas9	5'-NNGRRT-3'	Blunt DSB	dsDNA	In vivo AAV delivery
Base Editor (BE)	nCas9-deaminase	5'-NGG-3'	Single-base change	dsDNA	Point mutation correction
Prime Editor (PE)	nCas9-RT	5'-NGG-3'	Nick + reverse transcription	dsDNA	Precise insertions/corrections

2.2. Genome Engineering in Drug Discovery

CRISPR has transformed drug discovery pipelines by enabling precise genetic manipulation of cell lines and animal models. Loss-of-function screens using genome-wide CRISPR knockout libraries (e.g., the Brunello and GeCKO libraries) allow simultaneous interrogation of thousands of genes in a single experiment, identifying candidates essential for cell viability, drug sensitivity, or disease phenotypes [12]. This approach has been instrumental in identifying synthetic lethal interactions exploitable in oncology [13].

Gain-of-function screens using CRISPRa (CRISPR activation), wherein a catalytically inactive dCas9 fused to transcriptional activators (e.g., VPR, SAM systems) upregulates target genes, complement knockout approaches by revealing gene functions that promote resistance to therapy or tumor growth [14]. These tools collectively enable pharmaceutical researchers to define and validate therapeutic targets with greater confidence and at unprecedented scale. CRISPR-edited cell lines further serve as isogenic controls in drug screening assays, minimizing confounders from genetic background heterogeneity [15].

Disease modeling constitutes another major pharmaceutical utility. CRISPR-engineered human induced pluripotent stem cells (iPSCs) carrying patient-specific mutations enable the study of disease mechanisms in human cellular contexts previously inaccessible to researchers. Such models have been generated for Parkinson's disease, Alzheimer's disease, cardiomyopathies, and multiple monogenic disorders, providing platforms for drug screening and biomarker discovery [16]. As illustrated in Figure 1, the integration of CRISPR into drug discovery encompasses target identification, validation, disease modeling, and lead optimization phases.



Fig 1:

3. Therapeutic Applications of CRISPR

3.1. Gene Therapy for Genetic Disorders

Monogenic diseases represent the most clinically advanced application of CRISPR therapeutics. Hemoglobinopathies—specifically sickle cell disease (SCD) and beta-thalassemia—have been at the forefront. The first approved CRISPR-based medicine, Casgevy (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, employs CRISPR-Cas9 to disrupt the BCL11A enhancer in hematopoietic stem cells (HSCs), thereby reactivating fetal

hemoglobin (HbF) expression to compensate for defective adult hemoglobin [6, 17]. Clinical trial data demonstrated transfusion independence in the vast majority of treated patients.

Duchenne muscular dystrophy (DMD) represents another priority target. Exon-skipping strategies using CRISPR can restore a truncated but partially functional dystrophin reading frame, offering a potential treatment for this otherwise fatal disease [18]. Similarly, CRISPR-based approaches for Leber congenital amaurosis (LCA10 caused by CEP290 mutations) are being explored using *in vivo* delivery to retinal cells, with the EDIT-101 candidate from Editas Medicine advancing through Phase I/II trials [19].

Table 2 provides a comprehensive overview of therapeutic CRISPR applications across disease categories, and Figure 2 illustrates the principal strategies employed for genetic and infectious diseases.



Fig 2:

Table 2: Pharmaceutical and Biomedical Applications of CRISPR Technology

Disease Area	Target Gene/Pathway	CRISPR Strategy	Clinical Stage	Key Developer
Sickle Cell Disease	BCL11A enhancer	Ex vivo HSC editing (Cas9)	Approved (2023)	Vertex/CRISPR Tx
Beta-Thalassemia	BCL11A enhancer	Ex vivo HSC editing (Cas9)	Approved (2023)	Vertex/CRISPR Tx
Duchenne MD	Dystrophin exon skip	In vivo exon deletion (AAV)	Preclinical/Phase I	Multiple groups
Leber Congenital Amaurosis	CEP290	In vivo retinal editing (LNP)	Phase I/II	Editas Medicine
B-cell Malignancies	CD19/BCMA	CAR-T engineering (ex vivo)	Phase I/II	Allogene/Intellia
HIV Infection	CCR5 / HIV provirus	Disruption/excision (Cas9)	Preclinical/Phase I	Various
Transthyretin Amyloidosis	TTR gene	In vivo liver editing (LNP)	Phase I	Intellia Therapeutics
Hypercholesterolemia	PCSK9	In vivo base editing	Phase I	Verve Therapeutics

3.2. Applications in Cancer Treatment

Oncology represents one of the most dynamic areas of CRISPR therapeutic development. CRISPR has been leveraged to engineer chimeric antigen receptor T (CAR-T) cells with enhanced efficacy and reduced immunogenicity. Allogeneic ('off-the-shelf') CAR-T products are being developed by disrupting T-cell receptor (TCR) genes and MHC class I molecules to prevent graft-versus-host disease and immune rejection, respectively [20]. Multiplexed CRISPR editing enables simultaneous knockout of multiple inhibitory checkpoints (PD-1, LAG-3, TIM-3) in tumor-infiltrating lymphocytes to restore anti-tumor immunity.

In addition, CRISPR screens have identified critical tumor dependencies and synthetic lethal pairs that inform combination therapy strategies. For instance, genome-wide screens in glioblastoma and pancreatic cancer models have uncovered novel vulnerabilities to targeted agents [21]. CRISPR-engineered patient-derived xenograft (PDX) models more faithfully recapitulate tumor heterogeneity, improving preclinical predictive validity for oncology drug candidates [22].

3.3. CRISPR for Infectious Diseases

The programmable nuclease activity of CRISPR systems offers novel antiviral strategies. Cas9 and Cas12a have been employed to directly cleave and disrupt viral DNA genomes integrated into host cells, as demonstrated for HIV-1 provirus excision in latently infected cells [23]. Cas13-based platforms, which target RNA, have shown efficacy against a range of RNA viruses including influenza, SARS-CoV-2, and respiratory syncytial virus in preclinical models [10]. The CARVER (Cas13-Assisted Restriction of Viral Expression and Readout) platform systematically evaluated Cas13 antiviral efficacy across multiple viral families.

Hepatitis B virus (HBV), which establishes a persistent episomal covalently closed circular DNA (cccDNA) reservoir resistant to current antivirals, represents a compelling CRISPR target. Multiple preclinical studies have demonstrated efficient cccDNA cleavage using CRISPR-Cas9 delivered via AAV or LNP formulations [24].

4. CRISPR in Precision Medicine and Drug Development

4.1. Personalized Medicine Approaches

Precision medicine aims to tailor therapeutic interventions to individual genomic, proteomic, and clinical profiles.

CRISPR facilitates this vision by enabling patient-specific disease modeling and therapeutic development. iPSC lines derived from individual patients and edited with CRISPR to carry or correct specific mutations provide personalized in vitro platforms for predicting drug response and identifying optimal therapeutic regimens [16]. The workflow for CRISPR-mediated precision medicine is illustrated in Figure 3.



Fig 3:

4.2. High-Throughput Screening Using CRISPR

Pooled CRISPR library screens have revolutionized functional genomics and target discovery in pharmaceutical research. By infecting cell populations with lentiviral sgRNA libraries at low multiplicity of infection (MOI), researchers can link individual gene perturbations to phenotypic outcomes through next-generation sequencing of sgRNA representation before and after selection [12]. Such screens have identified drug resistance mechanisms, essential cancer genes, and drug sensitization targets across numerous disease models.

Arrayed CRISPR screens, in which individual genes are knocked out in separate wells, allow high-content imaging or multi-parameter assays not amenable to pooled formats. These approaches are being integrated into industrial-scale pharmaceutical screening platforms [15]. CRISPRi (CRISPR interference) using dCas9 fused to transcriptional repressors enables graded, reversible gene silencing—advantageous for essential gene studies where complete knockout causes lethality.

4.3. Functional Genomics in Pharmaceutical Research

CRISPR-based functional genomics tools have accelerated the identification of biomarkers, resistance mechanisms, and pharmacological targets. Epigenome editing using dCas9 fused to chromatin modifiers (DNMT3A, TET1, p300, KRAB) enables dissection of gene regulatory elements relevant to disease states and drug responses [14]. These tools have been instrumental in characterizing enhancer elements driving oncogene expression, informing therapeutic targeting of non-coding genomic regions.

CRISPR base editors—cytosine base editors (CBEs) and adenine base editors (ABEs)—enable single-nucleotide changes without DSBs, substantially expanding the range of correctable pathogenic point mutations. ABEs, for example, can convert A:T to G:C base pairs with high efficiency and minimal indel formation, addressing mutations responsible for conditions such as sickle cell disease (HBB E6V) and progeria (LMNA G608G) [25].

5. Challenges and Ethical Considerations

5.1. Off-Target Effects

A central safety concern for CRISPR therapeutics is unintended editing at genomic sites with partial complementarity to the sgRNA, termed off-target effects. Such events may disrupt tumor suppressor genes or activate oncogenes, posing genotoxic risks. High-fidelity Cas9 variants—including eSpCas9, HiFi Cas9, and evoCas9—exhibit substantially reduced off-target activity with maintained on-target efficiency [26]. Computational prediction tools (CRISPOR, Cas-OFFinder) and empirical methods (GUIDE-seq, CIRCLE-seq, DISCOVER-Seq) are employed to profile off-target landscapes in preclinical development [27].

5.2. Delivery Challenges

Efficient and safe delivery of CRISPR components to target tissues remains a major translational barrier. Viral vectors—predominantly AAV—offer efficient transduction but are limited by packaging capacity (~4.7 kb), immunogenicity, and integration risk [28]. Lipid nanoparticles (LNPs), which encapsulate CRISPR mRNA or ribonucleoprotein (RNP) complexes, offer favorable safety profiles and have enabled clinical translation for liver-targeted applications (e.g., Intellia's NTLA-2001 for transthyretin amyloidosis) [29]. Tissue-specific delivery to the CNS, lung, and muscle remains technically challenging, necessitating development of next-generation delivery platforms including polymeric nanoparticles, lipitoids, and extracellular vesicles.

5.3. Regulatory and Ethical Considerations

The regulatory pathway for CRISPR therapeutics is evolving. Both the FDA and EMA classify most CRISPR-based medicines as advanced therapy medicinal products (ATMPs) or gene therapy products, requiring rigorous CMC (chemistry, manufacturing, and controls) documentation, genotoxicity studies, and long-term follow-up [30]. The approval of Casgevy provided a landmark regulatory precedent, but the framework for *in vivo* systemic editing remains less defined.

Ethical concerns are particularly acute for germline editing—modifications to embryos or reproductive cells that would be heritable. Following the 2018 controversy surrounding the first claimed CRISPR-edited babies, major scientific bodies including the WHO and National Academies have called for moratoriums on clinical germline editing until safety, efficacy, and societal governance frameworks are established [31, 32]. Somatic cell editing, by contrast, has broader ethical consensus given its non-heritable nature, though issues of equitable access, consent, and long-term monitoring persist [33].

Table 3: Advantages, Limitations, and Safety Considerations of CRISPR-Based Therapies

Dimension	Advantages	Limitations / Challenges
Precision & Specificity	Single-nucleotide targeting via sgRNA; high on-target efficiency; base editors offer DSB-free correction	Off-target cleavage at partially complementary sites; mosaicism in *in vivo* editing
Versatility	Multiple Cas orthologs; knockout, activation, repression, base editing, prime editing modes available	PAM sequence constraints limit targetable sites for some Cas variants
Delivery	LNPs effective for liver; AAV for retina, CNS; RNP electroporation for ex vivo HSCs	Limited tissue targeting for *in vivo* delivery; AAV immunogenicity; LNP tropism constraints
Manufacturing	Scalable GMP production; well-characterized raw materials; iPSC platforms for cell therapies	High cost of clinical-grade manufacturing; complex QC for cell-based products
Clinical Safety	Favorable early clinical trial profiles; ex vivo editing reduces systemic exposure	Long-term genotoxicity data lacking; risk of insertional mutagenesis with AAV
Regulatory & Ethics	Established ATMP regulatory framework; growing clinical precedent (Casgevy approval)	Germline editing moratorium; evolving guidelines; equitable access challenges

6. Future Perspectives

The CRISPR field is advancing rapidly along multiple innovation axes that promise to further expand pharmaceutical applications. Prime editing, which employs a nickase Cas9 fused to an engineered reverse transcriptase and a pegRNA, enables all twelve types of point mutations and small insertions/deletions without DSBs or donor DNA templates, substantially broadening the correctable disease spectrum [34]. Epigenome editors offering sustained, heritable gene silencing without permanent DNA alteration may provide safer alternatives for conditions where complete gene knockout is undesirable.

CRISPR-based diagnostics (SHERLOCK, DETECTR, CARMEN platforms) leverage the collateral cleavage activity of Cas12 and Cas13 to achieve attomolar sensitivity for nucleic acid detection, with applications in infectious disease surveillance, oncology biomarker detection, and pharmacogenomic testing [35, 36]. Integration with microfluidics and portable devices may bring point-of-care genomic diagnostics to resource-limited settings.

In the sphere of next-generation cell therapies, CRISPR is enabling the engineering of allogeneic 'universal' CAR-T and CAR-NK cells with reduced immunogenicity, improved persistence, and enhanced tumor targeting [37]. Multiplexed editing strategies incorporating resistance to immune checkpoint inhibition and metabolic stress adaptation are being explored to overcome the immunosuppressive tumor microenvironment.

Finally, artificial intelligence and machine learning are increasingly being applied to sgRNA design optimization, off-target prediction, and CRISPR screen data analysis, compressing the timeline from target identification to clinical candidate nomination [38]. The convergence of CRISPR with other transformative technologies—organoids, single-cell sequencing, and spatial genomics—positions gene editing as a cornerstone of 21st-century pharmaceutical innovation [39, 40].

7. Conclusion

CRISPR technology has matured from a molecular biology tool into a clinically validated therapeutic platform with profound pharmaceutical implications. As discussed in this review, its applications span gene therapy for monogenic disorders, cancer immunotherapy, antiviral strategies, high-throughput drug discovery, and precision medicine. The landmark regulatory approval of Casgevy underscores the translational potential of CRISPR-based medicines. While challenges related to delivery, off-target effects, manufacturing, and ethics persist, ongoing technological innovations in base editing, prime editing, LNP delivery, and AI-guided design are systematically addressing these limitations. Continued interdisciplinary collaboration among molecular biologists, pharmaceutical scientists, clinicians, regulatory agencies, and bioethicists will be essential to fully realize the transformative potential of CRISPR for human health. The next decade is poised to witness an expansion of approved CRISPR therapeutics across a broad spectrum of diseases, fundamentally altering the pharmaceutical development paradigm.

References

1. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014;346(6213):1258096.
2. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337(6096):816-821.
3. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc*. 2013;8(11):2281-2308.
4. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, *et al*. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013;339(6121):819-823.
5. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends Biotechnol*. 2013;31(7):397-405.
6. Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, *et al*. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. *N Engl J Med*. 2021;384(3):252-260.
7. Anders C, Niewoehner O, Duerst A, Jinek M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. *Nature*. 2014;513(7519):569-573.

8. Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes. *Cell*. 2017;168(1-2):20-36.
9. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, *et al*. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell*. 2015;163(3):759-771.
10. Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, *et al*. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science*. 2016;353(6299):aaf5573.
11. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, *et al*. *in vivo* genome editing using Staphylococcus aureus Cas9. *Nature*. 2015;520(7546):186-191.
12. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, *et al*. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol*. 2016;34(2):184-191.
13. Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, *et al*. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. *Cell*. 2015;163(6):1515-1526.
14. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, *et al*. Genome-scale CRISPR-mediated control of gene repression and activation. *Cell*. 2014;159(3):647-661.
15. Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, *et al*. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. *Nature*. 2019;568(7753):511-516.
16. Hockemeyer D, Jaenisch R. Induced pluripotent stem cells meet genome editing. *Cell Stem Cell*. 2016;18(5):573-586.
17. Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, *et al*. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. *N Engl J Med*. 2021;384(3):205-215.
18. Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Bhattacharyya RD, *et al*. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. *Nat Commun*. 2017;8:14454.
19. Maeder ML, Stefanidakis M, Wilson CJ, Baral R, Barrera LA, Bounoutas GS, *et al*. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. *Nat Med*. 2019;25(2):229-233.
20. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, *et al*. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Sci Transl Med*. 2017;9(374):eaaj2013.
21. Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, *et al*. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. *Nat Protoc*. 2017;12(4):828-863.
22. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, *et al*. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. *Cell*. 2015;160(6):1246-1260.
23. Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y, *et al*. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. *Sci Rep*. 2016;6:22555.
24. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, *et al*. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates *in vivo*. *Mol Ther Nucleic Acids*. 2014;3:e186.
25. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, *et al*. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature*. 2019;576(7785):149-157.
26. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. *Science*. 2016;351(6268):84-88.
27. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, *et al*. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat Biotechnol*. 2015;33(2):187-197.
28. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. *Nat Rev Drug Discov*. 2019;18(5):358-378.
29. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, *et al*. CRISPR-Cas9 *in vivo* gene editing for transthyretin amyloidosis. *N Engl J Med*. 2021;385(6):493-502.
30. Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, *et al*. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. *Nature*. 2016;539(7629):384-389.
31. Lander ES, Baylis F, Zhang F, Charpentier E, Berg P, Liu C, *et al*. Adopt a moratorium on heritable genome editing. *Nature*. 2019;567(7747):165-168.
32. World Health Organization Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. Human genome editing: a framework for governance. Geneva: WHO; 2021.
33. Nuffield Council on Bioethics. Genome editing and human reproduction: social and ethical issues. London: Nuffield Council on Bioethics; 2018.
34. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. *Nat Biotechnol*. 2020;38(7):824-844.
35. Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, *et al*. Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science*. 2017;356(6336):438-442.
36. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, *et al*. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science*. 2018;360(6387):436-439.
37. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, *et al*. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor and anti-HIV activity. *Leukemia*. 2018;32(2):520-531.
38. Kim HK, Lee S, Kim Y, Park J, Min S, Choi JW, *et al*. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells. *Nat Biomed Eng*. 2020;4(1):111-124.
39. Huch M, Knoblich JA, Lutolf MP, Martinez-Arias A. The hope and the hype of organoid research. *Development*. 2017;144(6):938-941.
40. Rozenblatt-Rosen O, Stubbington MJT, Regev A, Teichmann SA. The Human Cell Atlas: from vision to reality. *Nature*. 2017;550(7677):451-453.